Fennec Pharmaceuticals Inc. (FENC)

US — Healthcare Sector
Peers: MOLN  MNOV  ANEB  CSBR  CYT  KROS  JANX  EWTX  HRMY    IKNA  AVTE  ELYM  DBTX  OLMA  IRON  LRMR  OBIO 

Automate Your Wheel Strategy on FENC

With Tiblio's Option Bot, you can configure your own wheel strategy including FENC - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol FENC
  • Rev/Share 1.1209
  • Book/Share 0.0903
  • PB 89.897
  • Debt/Equity 0.0
  • CurrentRatio 5.1338
  • ROIC -0.3151

 

  • MktCap 224263844.0
  • FreeCF/Share -0.5816
  • PFCF -13.9825
  • PE -15.9134
  • Debt/Assets 0.0
  • DivYield 0
  • ROE 5.8985

 

  • Rating D+
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Fennec Pharmaceuticals Inc. (FENC) Q1 2025 Earnings Call Transcript
FENC
Published: May 13, 2025 by: Seeking Alpha
Sentiment: Neutral

Fennec Pharmaceuticals Inc. (NASDAQ:FENC ) Q1 2025 Earnings Conference Call May 13, 2025 8:30 AM ET Company Participants Robert Andrade - Chief Financial Officer Jeff Hackman - Chief Executive Officer and Director Conference Call Participants Chase Knickerbocker - Craig Hallum Sudan Loganathan - Stevens Michael Okunewitch - Maxim Group Raghuram Selvaraju - H.C. Wainwright Operator Good morning, ladies and gentlemen.

Read More
image for news Fennec Pharmaceuticals Inc. (FENC) Q1 2025 Earnings Call Transcript
Wall Street Analysts See an 113.25% Upside in Adherex Technologies (FENC): Can the Stock Really Move This High?
FENC
Published: April 30, 2025 by: Zacks Investment Research
Sentiment: Positive

The average of price targets set by Wall Street analysts indicates a potential upside of 113.3% in Adherex Technologies (FENC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Read More
image for news Wall Street Analysts See an 113.25% Upside in Adherex Technologies (FENC): Can the Stock Really Move This High?
Fennec Pharmaceuticals Inc. (FENC) Q4 2024 Earnings Call Transcript
FENC
Published: March 10, 2025 by: Seeking Alpha
Sentiment: Neutral

Fennec Pharmaceuticals Inc. (NASDAQ:FENC ) Q4 2024 Earnings Conference Call March 10, 2025 8:30 AM ET Company Participants Robert Andrade - CFO Jeff Hackman - CEO and Board Member Conference Call Participants Chase Knickerbocker - Craig-Hallum Raghuram Selvaraju - H.C. Wainwright Felix Ampomah - Stephens Michael Okunewitch - Maxim Group Operator Good morning, ladies and gentlemen, and welcome to Fennec Pharmaceuticals Fourth Quarter and Full Year 2024 Earnings and Corporate Update Conference Call.

Read More
image for news Fennec Pharmaceuticals Inc. (FENC) Q4 2024 Earnings Call Transcript

About Fennec Pharmaceuticals Inc. (FENC)

  • IPO Date 2017-09-15
  • Website https://www.fennecpharma.com
  • Industry Biotechnology
  • CEO Mr. Jeffrey S. Hackman
  • Employees 32
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.